ReviewNature reviews. Neurology2021
Positron emission tomography in multiple sclerosis - straight to the target.
Review in Nature reviews. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05147532 (Remyelination in Multiple Sclerosis), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation
Who cites it
39 citing papers in PubMed.
- Impact of Oral Cladribine on TSPO-PET-Measurable Immune Cell Activation in Multiple Sclerosis.Neurology and therapy · 2026Article
- Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.Nature communications · 2026Article
- SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosis.PLoS computational biology · 2026Article
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- Investigating the association between grey matter hypoperfusion and atrophy in multiple sclerosis using arterial spin labelling.Brain communications · 2026Article
- Article
- First evaluation in multiple sclerosis using PET tracer [European journal of nuclear medicine and molecular imaging · 2026Article
- Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Multi-tracer PET and MR imaging visualize distinct metabolic and inflammatory profiles in the white matter of NMOSD and MOGAD.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Light and metabolism: label-free optical imaging of metabolic activities in biological systems [Invited].Biomedical optics express · 2025Review
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Biomarkers of Progression Independent of Relapse Activity-Can We Actually Measure It Yet?International journal of molecular sciences · 2025Review
- PET Beta-Amyloid Tracer Uptake in Leukoencephalopathies: Comparing Metachromatic Leukodystrophy and CADASIL.European journal of neurology · 2025Article
- Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress.Biomedicines · 2025Review
- Immune mechanisms and shared immune targets in neurodegenerative diseases.Nature reviews. Neurology · 2025Review
- Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire.Brain communications · 2025Article
- The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.Frontiers in immunology · 2025Review
- Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis.BMJ neurology open · 2025Article
- Predictors of risk of secondary progression in multiple sclerosis.Therapeutic advances in neurological disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the impressive progress in the treatment of relapsing-remitting multiple sclerosis (MS), the major challenge ahead is the development of treatments to prevent or delay the irreversible accumulation of clinical disability in progressive forms of the disease. The substrate of clinical progression is neuro-axonal degeneration, and a deep understanding of the mechanisms that underlie this process is a precondition for the development of therapies for progressive MS. PET imaging involves the use of radiolabelled compounds that bind to specific cellular and metabolic targets, thereby enabling direct in vivo measurement of several pathological processes. This approach can provide key insights into the clinical relevance of these processes and their chronological sequence during the disease course. In this Review, we focus on the contribution that PET is making to our understanding of extraneuronal and intraneuronal mechanisms that are involved in the pathogenesis of irreversible neuro-axonal damage in MS. We consider the major challenges with the use of PET in MS and the steps necessary to realize clinical benefits of the technique. In addition, we discuss the potential of emerging PET tracers and future applications of existing compounds to facilitate the identification of effective neuroprotective treatments for patients with MS.
Indexed as
Identifiers
34545219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.